Minnesota’s Synovis Life Technologies Inc. is being acquired by Baxter International Inc. in a $325 million deal, the companies announced today. Synovis’ board unanimously approved the buy at $28 per share. Pending shareholder approval, the deal is expected to close in the first quarter of 2012. The maker of biological and mechanical products for surgeries […]
Synovis Life Technologies Inc. announced Wednesday that the company had both top-line and bottom-line growth in its fiscal second quarter ended April 30. The St. Paul, Minnesota-based company saw revenue climb 12.6 percent to $19.8 million in the quarter, up from $17.6 million in the same quarter a year ago. Profits jumped 57.5 percent to […]
Synovis Life Technologies Inc. (NASDAQ:SYNO) may not have generated many headlines this year (which is not necessarily a bad thing), but the St. Paul company has quietly produced a rather impressive annual performance, especially compared to what remains of Minnesota's shrinking, publicly traded medical device sector.
Ernie Andberg has a little more free time on his hands these days. The long-time “emerging medical device companies” equity analyst for Feltl & Co. in Minneapolis has not seen a lot of companies emerging lately. In fact, they’ve been disappearing all together. Case in point: Medtronic Inc.’s (NYSE: MDT) deal last week to acquire […]
Device maker Synovis Life Technologies Inc. said its board of directors has authorized the company to repurchase up to 1 million shares of its common stock. Synovis’ board gave it plenty of leeway for the buyback. There’s no expiration date and no minimum purchase amount, according to a statement from the company. The company seeks […]
Synovis Life Technologies Inc. has received clearance from the U.S. Food and Drug Administration for a device that measures blood flow immediately after surgical procedures in which veins have been connected.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
